Cohort study finds no survival difference omitting CTV in unresectable stage III NSCLC, indicating a potential reduction in adverse effects.
Key Points
This study aims to evaluate the impact of omitting clinical target volume on survival and adverse effects in patients with unresectable stage III NSCLC undergoing radiotherapy.
Conducted a cohort analysis of patients with unresectable stage III NSCLC receiving radiation therapy.
Performed propensity score matching to align groups and control for confounding variables.
Compared survival outcomes and incidence of grade ≥2 radiation pneumonitis between groups with and without CTV.
No statistically significant difference in survival was found by omitting the clinical target volume.
Omission of the CTV may lead to a reduction in the incidence of grade ≥2 radiation pneumonitis.